DK Life Science Co., Ltd. (303810.KQ) stock: key figures, P/E, revenue and dividend

Health Care · South Korea

Price
1,724.00 KRW
Market cap
55.14 bn KRW
P/E (2025)
6.37
P/S (2025)
0.42
Dividend yield
0.00 %
Net margin
6.64 %
Return on equity (ROE)
6.59 %
Return on assets (ROA)
3.98 %

DK Life Science Co., Ltd. financials

Fiscal year20242025
Revenue131.82 bn KRW130.34 bn KRW
Gross profit28.59 bn KRW33.00 bn KRW
Operating income11.92 bn KRW13.05 bn KRW
EBIT12.74 bn KRW14.60 bn KRW
Net income2.24 bn KRW8.66 bn KRW
Diluted EPS – continuing operations70.18 KRW270.70 KRW

Full history since 2022, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About DK Life Science Co., Ltd.

DK Life Science Co., Ltd., a pharmaceutical company, develops and sells diagnostic medicines and medical devices in South Korea and internationally. It offers active pharmaceutical ingredients (API), injections, blood glucose self-monitoring device, Mobile CT equipment, and ultrasonic instruments. The company also offers catheters, MRI, CT scanner, ultrasound, mobile CT scanner, and X-ray equipment, as well as mammography image analysis assistance software. DK Life Science Co., Ltd. was founded in 2017 and is based in Seoul, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 16.11.2026. Details in the risk notice.